中環股份(002129.SZ):第二期員工持股計劃持有的340.44萬股已出售完畢
格隆匯3月25日丨中環股份(002129.SZ)公佈,基於第二期員工持股計劃員工有投資等方面的資金需求,截至2022年3月25日,公司第二期員工持股計劃持有的公司股票340.44萬股,佔公司目前總股本的0.11%,已通過二級市場集中競價方式全部出售完畢。
第二期員工持股計劃出售完畢後,公司仍存續有2021年員工持股計劃,持股數量合計897.5906萬股,佔公司總股本的0.28%;同時,公司已回購的庫存股票合計967.6878萬股,可用於員工持股計劃或者股權激勵,佔公司總股本的0.30%。以上兩項合計1865.2784萬股,佔公司總股本的0.58%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.